A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age
NCT07117487
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
507
Enrollment
INDUSTRY
Sponsor class
Conditions
Respiratory Syncytial Virus
Interventions
BIOLOGICAL:
mRNA-1345
Sponsor
ModernaTX, Inc.